Table 6 Net Benefit for different models at 17-year time point in participants with overweight/obese BMI SDS and all participants, predicting NAFLD fibrosis outcomes at 24 years
From: Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Model | Net benefit at risk threshold of 0.1 (median (IQR)) | |
|---|---|---|
Participants with overweight/obese BMI SDS | All participants | |
Treat All | − 0.0748 (− 0.0858 to − 0.0620) | − 0.0841 (− 0.0963 to − 0.0722) |
Treat None | 0 (0) | 0 (0) |
Routine clinical measures | 0.0054 (0.0034 to 0.0074) | 0.0012 (0.0009 to 0.0019) |
Cardiometabolic factors and Liver enzymes | 0.0052 (0.0033 to 0.0070) | − 0.0003 (− 0.0006 to − 0.0005) |
Liver enzymes | 0.0019 (0.0012 to 0.0029) | 0.0000 (− 0.0002 to 0.0003) |
Cardiometabolic factors | 0.0015 (0.0023 to 0.0052) | 0.0006 (0.0002 to 0.0009) |
Dyslipidaemia | 0.0010 (− 0.0002 to 0.0018) | 0.0004 (0.0001 to 0.0009) |
Central adiposity | 0.0001 (− 0.0004 to 0.0007) | 0.0001 (− 0.0004 to 0.0007) |
Insulin Resistance | 0.0004 (− 0.0002 to 0.0008) | − 0.0002 (− 0.0004 to 0.0001) |
Hypertension | 0.0008 (0.0004 to 0.0015) | − 0.0001 (− 0.0003 to 0.0001) |
BMI | − 0.0001 (− 0.0001 to − 0.0008) | − 0.0002 (− 0.0004 to − 0.0000) |
BMI and steatosis | − 0.0001(− 0.0009 to 0.0011) | − 0.0003 (− 0.0005 to 0.0001) |